Center for Inflammation Research, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
EMBO Mol Med. 2021 Jan 11;13(1):e13589. doi: 10.15252/emmm.202013589. Epub 2020 Dec 17.
Sepsis causes unacceptably high amounts of deaths worldwide. It is a huge unmet medical need, and new therapeutic interventions for sepsis and septic shock are urgently needed. By studying the mechanism by which a bacterial protein undermines the inflammatory function of macrophages, Kim et al, in the last issue of EMBO Molecular Medicine, have developed a new therapeutic protein drug, which appears to have very promising protective activities in a well-validated and aggressive polymicrobial sepsis model in mice. The chimeric protein is thought to limit macrophage inflammation while activating phagocytosis, and so, it hits two macrophage pathways at once.
败血症在全球范围内导致了极高的死亡率。这是一个巨大的未满足的医疗需求，迫切需要新的治疗败血症和感染性休克的干预措施。通过研究一种细菌蛋白破坏巨噬细胞炎症功能的机制，Kim 等人在《EMBO 分子医学》的最后一期中开发了一种新的治疗性蛋白药物，该药物似乎在一种经过充分验证和具有侵袭性的多微生物败血症小鼠模型中具有非常有前景的保护活性。这种嵌合蛋白被认为可以限制巨噬细胞炎症，同时激活吞噬作用，因此，它同时作用于两种巨噬细胞途径。
